Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Elderly Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa

NCT01149629
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
65 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers

NCT02691702
View directory record Official record
Conditions
Healthy Adult Subjects, Healthy Elderly Subjects
Interventions
BIIB118, Melatonin
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

NCT01079819
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BMS-708163, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Cypress, California • Glendale, California • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2011 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects

NCT01161472
View directory record Official record
Conditions
Healthy
Interventions
4mg fesoterodine, 8mg fesoterodine, alprazolam 1mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

I.V. Selonabant in Healthy Adult Subjects

NCT07211607
View directory record Official record
Conditions
Healthy Volunteers
Interventions
selonabant, placebo
Drug
Lead sponsor
Anebulo Pharmaceuticals
Industry
Eligibility
18 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 24, 2026, 4:57 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

NCT07144527
View directory record Official record
Conditions
Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
Interventions
NMN, betaine, low-dose hydrogen peroxide (EGA), Nicotinamide Mononucleotide (NMN), Placebo
Dietary Supplement
Lead sponsor
Scott Silveira
Other
Eligibility
60 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects

NCT01365624
View directory record Official record
Conditions
Healthy Subjects
Interventions
Ketorolac tromethamine
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Jul 24, 2026, 4:57 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649

NCT02170012
View directory record Official record
Conditions
Healthy Elderly
Interventions
PF-06743649, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine

NCT00224471
View directory record Official record
Conditions
Herpes Simplex
Interventions
GSK208141 vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 17 Years · Female only
Enrollment
671 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
9
States / cities
Mesa, Arizona • Fountain Valley, California • Golden, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of RO4995819 in Healthy Elderly Volunteers

NCT01457664
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Placebo, RO4995819
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
65 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

NCT00369824
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Different formulations of GSK Biologicals' HPV vaccine (580299), Menactra TM, Boostrix TM
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 18 Years · Female only
Enrollment
1,330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
50
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Walnuts and Healthy Aging

NCT01634841
View directory record Official record
Conditions
Age Related Cognitive Decline, Age Related Macular Degeneration
Interventions
Walnuts, habitual diet
Dietary Supplement · Other
Lead sponsor
Loma Linda University
Other
Eligibility
63 Years to 79 Years
Enrollment
708 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Results available

SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

NCT02036645
View directory record Official record
Conditions
Mild-Moderate Alzheimer's Disease, Healthy Elderly
Interventions
MEDI1814 for IV injection, MEDI1814 for Subcutaneous Injection, IV Placebo, Placebo for Subcutaneous Injection
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Glendale, California • Long Beach, California • Panorama City, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.

NCT00959803
View directory record Official record
Conditions
Healthy
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2009 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

NCT01461980
View directory record Official record
Conditions
Vaccines, Meningococcal Vaccines
Interventions
rLP2086 + MCV4 + Tdap, MCV4 + Tdap + saline, rLP2086 + saline
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 12 Years
Enrollment
2,648 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
117
States / cities
Birmingham, Alabama • Daphne, Alabama • Chandler, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

NCT02509117
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06751979 single ascending dose, Placebo single dose, PF-06751979 multiple ascending dose, Placebo multiple dose, PF-06751979 multiple dose
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55

NCT07019064
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

NCT00761631
View directory record Official record
Conditions
Healthy Subjects
Interventions
13 valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
15 Months to 18 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Benton, Arkansas • Fayetteville, Arkansas • Jonesboro, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

NCT00783926
View directory record Official record
Conditions
Influenza, Pandemic Influenza
Interventions
H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
6
States / cities
Wichita, Kansas • Lexington, Kentucky • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Jul 24, 2026, 4:57 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects

NCT05653258
View directory record Official record
Conditions
Obesity, Healthy Lifestyle
Interventions
Lifestyle Intervention, Dasatinib 100 MG, Quercetin 1000mg, Placebo, Abdominal adipose tissue biopsy
Other · Drug · Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide

NCT01366365
View directory record Official record
Conditions
Healthy Adults
Interventions
methylnaltrexone, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects

NCT00694044
View directory record Official record
Conditions
Healthy, Non-Smoking
Interventions
varenicline, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2009 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects

NCT02587520
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis, Whooping Cough
Interventions
Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4, Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years and older
Enrollment
1,363 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
20
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Jul 24, 2026, 4:57 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects

NCT05363293
View directory record Official record
Conditions
Alzheimer's Disease, Healthy Non-elderly and Elderly Adults
Interventions
AL001, Placebo
Drug · Other
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Jul 24, 2026, 4:57 PM EDT